Valuation: Islet Holdings, Inc.

Market Cap 894K 794K 743K 677K 1.27M 86.11M 1.29M 8.99M 3.48M 43.85M 3.36M 3.29M 141M P/E 2000
-5.66x
P/E 2001 -3.18x
Enterprise Value 348K 309K 289K 264K 496K 33.54M 503K 3.5M 1.36M 17.08M 1.31M 1.28M 54.86M EV / Sales 2000
9.04x
EV / Sales 2001 23.1x
Free-Float
99%
Yield 2000 *
-
Yield 2001 -
3 years 0
Extreme 0.0001
0
5 years 0
Extreme 0.0001
0
10 years 0
Extreme 0.0001
1
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-50.00% 21.3K
-0.62%-2.71%+39.30%+114.07% 1,025B
-2.30%-4.44%+39.03%+66.07% 623B
-0.63%-1.96%+6.36%+74.38% 459B
-1.03%-2.82%+59.56%+39.69% 355B
-0.37%-3.22%+22.65%+40.58% 336B
-0.17%-1.32%+13.65%+26.61% 270B
-0.29%-4.24%-3.48%+9.77% 247B
-3.38%+0.30%+36.44%+51.54% 220B
-1.04%-1.46%+32.70%+96.82% 183B
Average -0.99%-1.70%+24.62%+46.95% 371.82B
Weighted average by Cap. -1.05%-2.11%+30.42%+69.56%

Financials

2000 2001
Net sales 727K 645K 604K 550K 1.04M 69.97M 1.05M 7.3M 2.83M 35.64M 2.73M 2.67M 114M 637K 565K 529K 482K 907K 61.29M 920K 6.4M 2.48M 31.21M 2.39M 2.34M 100M
Net income -1.01M -897K -839K -765K -1.44M -97.28M -1.46M -10.15M -3.93M -49.54M -3.79M -3.71M -159M -3.42M -3.04M -2.84M -2.59M -4.88M -330M -4.95M -34.4M -13.32M -168M -12.85M -12.58M -539M
Net Debt 287K 255K 238K 217K 409K 27.63M 415K 2.88M 1.12M 14.07M 1.08M 1.05M 45.19M -546K -485K -454K -413K -778K -52.57M -789K -5.49M -2.12M -26.77M -2.05M -2.01M -85.99M
Logo Islet Holdings, Inc.
Islet Holdings Inc. is a biotechnology company, which is focused on cosmeceuticals. The Company is engaged in the research, development and commercialization of patented technologies in the field of transplantation in the therapy of people with conditions of insulin-dependent diabetes. The Company is developing intellectual property relating to hemp farming and extraction of cannabidiol (CBD) from hemp. Its technology constitutes methods for isolating, culturing, cryopreservation and immune-protection (microencapsulation) of islet cells. The Company's product candidates are intended for the treatment of insulin-dependent diabetes and are intended to be administered into the patient's abdominal cavity, where the transplanted islet cells will produce insulin in response to increase in blood glucose. The primary function of microencapsulation is to protect the islets from the host's immune system. The microcapsule coating is composed of layers of biocompatible materials.
Employees
13
  1. Stock Market
  2. Stocks
  3. ISHI Stock